The Alliance for Regenerative Medicine Announces Fourth Annual 2016 European Advanced Therapies Investor Day

– September 27, 2016

WASHINGTON, DC, September 28, 2016 – The Alliance for Regenerative Medicine (ARM), the international advocacy organization representing the cell and gene therapy and broader regenerative medicine sector, announced its annual European Advanced Therapies Investor Day will be held November 3, 2016 in London.

Now in its fourth year, this conference is the only European-centric investor meeting focused exclusively on the advanced therapy sector. This one-day program provides institutional, corporate and venture investors with exclusive access to this dynamic sector, offering unique, investment-driven insights into the state of clinical and commercial progress and development for advanced therapies.

“Continued clinical progress and infrastructure growth are essential to moving this industry forward,” said Morrie Ruffin, ARM managing director. “This annual event provides the investor community tailored, focused information about the very latest in cell and gene therapies, offering unparalleled insights and access to this promising field.”

Expected to attract more than 200 attendees, the program features executives from large pharmaceutical and enabling tool and service providers currently leading sector investment and partnerships. Clinical and commercial experts will address specific questions regarding the outlook for advanced therapies, as well as offer insight into how these technologies could impact the standard of care in key therapeutic areas. Attendees will also hear from life science investment experts and analysts covering the sector.

Several promising European and international advanced therapies companies will present, including Abeona Therapeutics; Adaptimmune; BioLife Solutions; Capricor Therapeutics; CellProthera; Kiadis Pharma; MaxCyte; Oxford BioMedica; ReNeuron; Synpromics; and TxCell.

A detailed preliminary agenda and speaker list is available on the event website

Registration is complimentary for credentialed investors and members of the media, however an RSVP is required. To learn more and to register, please visit For members of the media interested in attending, please contact Lyndsey Scull at

About The Alliance for Regenerative Medicine

The Alliance for Regenerative Medicine (ARM) is an international multi-stakeholder advocacy organization that promotes legislative, regulatory and reimbursement initiatives necessary to facilitate access to life-giving advances in regenerative medicine worldwide. ARM also works to increase public understanding of the field and its potential to transform human healthcare, providing business development and investor outreach services to support the growth of its member companies and research organizations. Prior to the formation of ARM in 2009, there was no advocacy organization operating in Washington, D.C. to specifically represent the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today, ARM has more than 250 members and is the leading global advocacy organization in this field. To learn more about ARM or to become a member, visit

# # #